ICOS antibody

Catalog No. ABIN475848

This anti-ICOS antibody is a Mouse Monoclonal antibody detecting ICOS in IHC, FACS, IP and IHC (fro). Suitable for Human.

Quick Overview for ICOS antibody (ABIN475848)

Target: ICOS (Inducible T-Cell Co-Stimulator (ICOS))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This ICOS antibody is un-conjugated

Application: Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunoprecipitation (IP), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: ISA-3

Product Details anti-ICOS Antibody

Purification: Affinity purified

Immunogen: Human ICOS

Isotype: IgG1 kappa

Application Details

Application Notes: Approved: Flo, IHC, IHC-Fr, IP

Usage: The ISA-3 antibody has been tested by flow cytometric analysis of unstimulated and PHA-activated (2 days) human blood leukocytes. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (ug) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Not recommended for: IHC-P

Comment:

Target Species of Antibody: Human

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: PBS,  pH 7.2, 150 mM sodium chloride, 0.09 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: avoid freezing and store undiluted.

Storage: 4 °C

Storage Comment: Store at 4°C, avoid freeze-thaw cycles.

Target Details for ICOS

Target: ICOS (Inducible T-Cell Co-Stimulator (ICOS))

Alternative Name: ICOS / CD278

Background: Name/Gene ID: ICOS

Synonyms: ICOS, AILIM, CD278, CVID1, Inducible costimulator, Inducible T-cell co-stimulator, CD278 antigen, Inducible T-cell costimulator

Gene ID: 29851

UniProt: Q9Y6W8

Pathways: Cancer Immune Checkpoints